Leila Nicolas
Investment Director @ GO CAPITAL
Rennes, France
Leila Nicolas is a seed investor at GO CAPITAL in Rennes focused on Biotechnology and Health Care. Leila Nicolas - Investment Director @ GO CAPITAL
- Total investments:
- 8
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Leila Nicolas invests in
Stages Leila Nicolas invests in
Countries Leila Nicolas invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 5 (63%)
- Health Care 4 (50%)
- Medical Device 3 (38%)
- Medical 2 (25%)
- Biopharma 2 (25%)
Stage
- Seed 3 (38%)
- Series A 2 (25%)
- Series B 2 (25%)
- Venture - Series Unknown 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| BrightHeart is a medical technology startup that is developing artificial intelligence software to help diagnose congenital heart abnormalities in foetuses. | $12.8M / Series A / Jan 08, 2026 | ||
| Sirius NeoSight is a biotech and pharmaceutical company that detects subclinical neo-cancers and provide treatment for it. | $4.6M / Seed / Feb 04, 2025 | ||
|
Brightflow
|
Brightflow operates as a medical device startup. | $18.2M / Series A / Sep 10, 2024 | |
Abcely
|
Abcely is a biotech firm that is working on a novel anti-cancer medication. | $2.6M / Seed / Sep 21, 2023 | |
| VitaDX is a startup applying artificial intelligence to the healthcare sector, and more specifically to the early diagnosis of cancer by exploiting fluorescence imaging in favor of a first product, VisioCyt®, dedicated to the detection of cancer of the bladder. This solution will allow the diagnosis of bladder cancer from a simple urine sample toimprove the performance of urinary cytology conventionally used in first intention. | $1.2M / Venture - Series Unknown / Sep 04, 2020 | ||
| Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 milliondies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.Acticor Biotech was founded in November 2013 and is headquartered in Paris, France. | $7.7M / Series B / Nov 06, 2019 | ||
| Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to itsouter membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria. | $10.7M / Series B / Jan 16, 2018 | ||
| VitaDX is a startup applying artificial intelligence to the healthcare sector, and more specifically to the early diagnosis of cancer by exploiting fluorescence imaging in favor of a first product, VisioCyt®, dedicated to the detection of cancer of the bladder. This solution will allow the diagnosis of bladder cancer from a simple urine sample toimprove the performance of urinary cytology conventionally used in first intention. | $1.8M / Seed / Jun 06, 2017 |
Co-Investors
About GO CAPITAL
GO Capital is an independent management company and a major player in regional Seed and Venture Capital since 2003. With offices in Brittany, Pays de la Loire, Normandy, Centre-Val de Loire and the South of France, GO Capital contributes to the financing of responsible innovation in these regions. With a team of investors with complementarysectoral experience, we have a solid track-record in DeepTech. GO Capital has nearly 400 million euros under management, and mainly finances technology leaders in the digital and healthcare sectors and in the industry of the future.
GO CAPITAL Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Aude Kermarrec
Administration
|
|||
Frederic Le Brun
Partner
|
|||
Hervé BACHELOT LALLIER
Associate Investment Director
|
|||
Jerome Gueret
Managing Director
|
|||
|
Leila Nicolas
Investment Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Leila Nicolas invest in?
Leila Nicolas invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Seed and Series A stage. Most of the 8 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Leila Nicolas?
Public channels for Leila Nicolas include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Leila Nicolas last invest?
The most recent investment recorded for Leila Nicolas closed in Jan 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
